25/08/2026
Business China Chairman Mr Lee Yi Shyan recently welcomed Mr Li Xiaojun, Party Secretary and Chairman of Guangzhou Pharmaceutical Holdings Limited (GPHL), and his senior delegation during their visit to Singapore.
A Fortune Global 500 enterprise, GPHL is the first company with traditional Chinese medicine as its core business to enter the list. The Group is actively advancing its innovation-driven transformation and expanding its international presence. 🌐
The meeting brought together senior representatives from GPHL and its listed subsidiary, Guangzhou Baiyunshan Pharmaceutical Holdings, as well as Singapore-based Lion TCR. An Agency for Science, Technology and Research (A*STAR) spin-off, Lion TCR is a clinical-stage biotechnology company developing T-cell therapies for virus-related cancers and chronic viral infections. 🦠
Discussions explored opportunities for closer Guangzhou–Singapore cooperation in healthcare innovation, research commercialisation, talent exchange, and product and market development. 🧬
Business China is pleased to facilitate such connections and looks forward to supporting further exchanges and partnerships between organisations in Singapore and Guangzhou.🤝
通商中国主席李奕贤先生近日接待来新加坡访问的广州医药集团有限公司(广药集团)党委书记、董事长李小军先生及其高层代表团一行。作为全球首家以中医药为核心业务跻身《财富》世界500强的企业,广药集团目前正在全力推进创新驱动转型与拓展海外布局。🌐
参加会见的还包括来自广药集团旗下上市子公司广州白云山医药集团股份有限公司以及来自新加坡的来恩生物公司的负责人。来恩生物是一家从新加坡科技研究局(A*STAR)孵化的临床阶段生物技术公司,专注于开发T细胞疗法治疗病毒相关癌症和慢性病毒感染。🧬
双方就深化广州与新加坡合作开展了深入交流,重点探讨了在医疗创新、研发商业化、人才交流、产品市场推广方面的合作机遇。🦠
通商中国致力于搭建促进高层往来的交流平台,并将持续支持广州与新加坡两地的机构开展更多交流与合作。🤝